Gyre Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

Gyre Therapeutics

10/08/2026 13:00

Gyre Therapeutics, Inc. GYRE.OQ reported a quarterly adjusted loss of 12 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 2 cents.  The mean expectation of three analysts for the quarter was for a loss of 9 cents per share. 
Revenue rose 8.7% to $29.11 million from a year ago; analysts expected $26.49 million. 
Gyre Therapeutics, Inc.'s reported EPS for the quarter was a loss of 12 cents​.
The company reported a quarterly loss of $11.66 million.
Gyre Therapeutics, Inc. shares had risen by 1.2% this quarter and lost 5.5% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Gyre Therapeutics, Inc. is $18.00, about 62.9% above its last closing price of $6.67
This summary was machine generated from LSEG data August 10 at 12:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.09
-0.12
Missed
Mar. 31 2026 
-0.07
-0.04
Beat
Dec. 31 2025 
0.06
0.05
Missed
Sep. 30 2025 
0.03
0.08
Beat